Table 2.
Distribution of vaccine types and them adverse events presented in at least 1% of ITP patients diagnosed before pandemic.
| Vaccination | Patient, n. (%) | Overall, n. (%) | Arm Pain, n. (%) | Fever, n. (%) | Fatigue, n. (%) | Headache, n. (%) | Arthromyalgia, n. (%) | Gastrointestinal disorders, n. (%) | Lymphoadenomegaly, n. (%) |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Vaccine type received at 1° dose | 360 (100) | 113 (31.3) | 52 (14.4) | 35 (9.7) | 22 (6.1) | 11 (3.1) | 7 (1.9) | 2 (0.6) | 1 (0.3) |
| mRNA-BNT162b2 [Pfizer] | 272 (75.6) | 78 (28.6) | 40 (14.7) | 20 (7.3) | 13 (4.8) | 7 (2.6) | 5 (1.8) | 1 (0.4) | 1 (0.4) |
| mRNA-1273 [Moderna] | 50 (13.8) | 21 (42.0) | 9 (18.0) | 8 (16.0) | 7 (14.0) | 1 (2.0) | 1 (2.0) | 0 (0) | 0 (0) |
| ChAdOx1-S [Astra Zeneca] | 33 (9.2) | 14 (42.4) | 3 (9.1) | 7 (21.2) | 2 6.1) | 3 (9.0) | 1 (3.0) | 1 (3.0) | 0 (0) |
| Ad26-COV2-S [Johnson & Johnson] | 5 (1.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
|
| |||||||||
| Vaccine type received at 2° dose | 342 (100) | 121 (35.4) | 47 (13.7) | 44 (12.9) | 23 (6.7) | 14 (4.1) | 12 (3.5) | 3 (0.9) | 4 (1.2) |
| mRNA-BNT162b2 | 266 (77.8) | 93 (35.0) | 38 (14.3) | 33 (12.4) | 18 (6.8) | 11 (4.1) | 8 (3.0) | 3 (1.1) | 3 (1.1) |
| mRNA-1273 | 46 (13.4) | 22 (47.8) | 6 (13.0) | 10 (21.7) | 4 (8.7) | 2 (4.3) | 3 (6.5) | 0 (0) | 1 (2.1) |
| ChAdOx1-S | 30 (8.8) | 6 (20) | 3 (3.3) | 3 (3.3) | 3 (3.3) | 3 (3.3) | 3 (3.3) | 0 (0) | 0 (0) |
|
| |||||||||
| Vaccine type received at booster | 313 (100) | 119 (38.0) | 43 (13.7) | 42 (13.4) | 24 (7.7) | 20 (6.4) | 16 (5.1) | 2 (0.6) | 5 (1.6) |
| mRNA-BNT162b2 | 119 (38.0) | 36 (30.2) | 14 (11.7) | 9 (7.6) | 9 (7.6) | 5 (4.2) | 4 (3.4) | 1 (0.8) | 1 (0.84) |
| mRNA-1273 | 194 (62.0) | 83 (42.8) | 29 (14.9) | 33 (17.0) | 15 (7.7) | 15 (7.7) | 12 (6.2) | 1 (0.5) | 4 (2.1) |